A Standardized Vascular Disease Health Check in Europe: A Cost-Effectiveness Analysis

• C. Andy Schuetz ,

  * E-mail: andy.schuetz@archimedesmodel.com

  Affiliation Archimedes, Inc., San Francisco, California, United States of America

  ⨯
• Peter Alperin,

  Affiliation Archimedes, Inc., San Francisco, California, United States of America

  ⨯
• Swathi Guda,

  Affiliation Archimedes, Inc., San Francisco, California, United States of America

  ⨯
• Andrew van Herick,

  Affiliation Archimedes, Inc., San Francisco, California, United States of America

  ⨯
• Bertrand Cariou,

  Affiliation Clinique d'Endocrinologie, l'Institut du Thorax, CHU Nantes, Nantes, France

  ⨯
• David Eddy,

  Affiliation Archimedes, Inc., San Francisco, California, United States of America

  ⨯
• Janusz Gumprecht,

  Affiliation Department of Internal Diseases, Diabetology and Nephrology, Medical University of Silesia, Zabrze, Poland

  ⨯
• Antonio Nicolucci,

  Affiliation Department of Clinical Pharmacology and Epidemiology, Consorzio Mario Negri Sud, Santa Maria Imbaro, Italy

  ⨯
• Peter Schwarz,

  Affiliation Department of Medicine III Prevention and Care of Diabetes , University of Dresden, Dresden, Germany

  ⨯
• Nick J. Wareham,

  Affiliation Medical Research Council Epidemiology Unit, Institute of Metabolic Science, Addenbrooke's Hospital, Cambridge, United Kingdom

  ⨯
• Daniel R. Witte,

  Affiliation Steno Diabetes Center, Gentofte, Denmark

  ⨯
• Ulf Smith

  Affiliation Sahlgrenska University Hospital, Gothenburg, Sweden

  ⨯